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The American Journal of Pathology has developed a formal Scientific Integrity
Policy in an effort to define more clearly issues of scientific misconduct in journal
publishing. This document defines common issues relating to appropriate scientific
conduct as well as the procedures that will be followed should misconduct issues
arise. In addition the Instructions to Authors (http://ajp.amjpathol.org) and Instruc-
tions to Reviewers (http://jmd.amjpathol.org/) have been updated to reflect these
changes.
The policy is based on recommendations from the Uniform Requirements for Manu-
scripts Submitted to Biomedical Journals (http://www.icmje.org), the CSE White
Paper on Promoting Integrity in Scientific Journal Publications (http://www.council-
scienceeditors.org/editorial_policies/white_paper.cfm), and the US Department of
Health and Human Services’ Office of Research Integrity (http://ori.dhhs.gov/). It
should be noted that willful misconduct does not include incidents of honest mis-
judgment or inadvertent error. Any questions regarding the official policy of the
Journal should be directed to the Editorial Office at 301-634-7959 or ajp@asip.org.
Author Conduct
General Authorship Guidelines. Uniform Requirements for Manuscripts Submit-
ted to Biomedical Journals (http://www.icmje.org) defines authorship as “1) substan-
tial contributions to conception and design, or acquisition of data, or analysis and
interpretation of data; 2) drafting the manuscript or revising it critically for important
intellectual content; and 3) final approval of the version to be published. Authors
should meet conditions 1, 2, and 3.” When work has been performed by a large,
multi-center group, the group should designate individuals who accept direct re-
sponsibility for the manuscript on behalf of the group. These individuals should fully
meet the criteria above and should disclose conflicts of interest (see below) on
behalf of the group. All members of the group who meet authorship criteria should
be provided for listing as a footnote.
When submitting a manuscript to the Journal, the corresponding author takes
responsibility on behalf of all authors for the authorship, authenticity and integrity of
the research being reported. The email contact information of ALL authors is re-
quired so the Journal may formally contact the authors regarding any aspect of
manuscript submission. If an author is removed during the course of revision of the
manuscript, written explanation and consent by the removed author (signed letter or
personal email) should be provided. Any change made to the list of authors (addi-
tion, removal, change in order) after manuscript acceptance requires consent of all
authors and editorial approval. Authorship disputes are to be resolved by the authors
and/or their institutions, not by the Journal.
Because inclusion in the Acknowledgments may give the appearance of endorse-
ment of the manuscript and its findings, authors should obtain permission from all
individuals named in the Acknowledgments who contributed substantially to the
work reported (eg, data collection, analysis, or writing/editing assistance) but did not
fulfill the authorship criteria. Likewise, authors should receive permission from all
individuals named as sources for personal communication or unpublished data.
Such permissions should be affirmed by the corresponding author in the cover letter.
Ghostwriting. As stated above, all persons contributing to the paper but not meet-
ing authorship criteria should be listed in the Acknowledgments section. Further, any
funding for writing support should be fully disclosed. If an outside source funded the
assistance, the authors of the paper should also affirm that they are solely, and
independently, responsible for the interpretation of the data and that they had full
and open access to all of the data. It is considered unethical for any entity (eg,
governmental, private, or commercial) with direct financial or personal interests to
restrict the use of data or their interpretation for the sole purpose of presenting data
in a manner that is favorable to its own interests or those of its affiliates. It is also
unethical for any entity to be responsible for data gathering, interpretation, and/or
presentation and then to solicit outside “authors” for the paper, as a means of hiding
its relationship with the data.
Peer Review Process. The Journal takes great care to secure the confidentiality
and integrity of the peer-review process. It is the practice of the Journal to conduct
a blinded peer-review process. Thus, it is considered a violation of this process for
authors to identify or attempt to communicate directly with peer reviewers or Asso-
ciate Editors regarding their manuscript. The Editors will consider any deliberate
ethical violation in either the reported research or the manuscript preparation and
review to be actionable misconduct, the potential results of which may be manu-
script rejection or public article retraction, reporting of conduct to the authors’
governing institutions, and/or the denial to consider any future submissions to the
Journal.
Authors may request that specific reviewers not be used due to prior collaborations,
known conflicts of interest, or direct competition. The Editors will make every effort
to respect requests that are well-founded; however, the Editors do have the authority
to utilize such a reviewer if it is necessary for expert peer review.
To aid the review process, authors should be ready to comply with Editors’ requests
for copies of any similar works in preparation, copies of cited manuscripts that are
submitted or in press, and/or supporting manuscript data (eg, data not shown but
summarized in the manuscript). Failure to do so may result in rejection of the
manuscript without further review.
Financial Disclosure and Conflicts of Interest. All authors must disclose any
current or former affiliations (eg, employment, consultancies, board membership,
stock ownership, funding, honoraria, expert testimony, patents or royalties, travel
reimbursements, industry-supplied free reagents, etc) with any organization or entity
having a direct financial or personal interest in the subject matter or materials
discussed in the manuscript. Authors should err on the side of full disclosure and
should contact the Editorial Office if they have questions or concerns. This informa-
tion should be provided at the time of submission (for new and revisedmanuscripts).
All authors will be required to complete an online disclosure form following accep-
tance; details are provided in the acceptance letter. Failure to disclose conflicts of
interest may result in manuscript rejection or editorial retraction of the article.
Ethical Treatment of Research Subjects. If human subjects or samples were
used, authors must affirm that the research protocol was approved by the appro-
priate institutional review boards or ethics committees for human (including use of
human cells or tissues) experiments and that all human subjects provided appro-
priate informed consent. To protect patient privacy, identifying information such as
names, initials, or hospital numbers should not be published unless the information
is essential for scientific purposes and the patient (or parent or guardian) gives
written informed consent for publication. If race/ethnicity is reported, authors should
state who determined race/ethnicity, how the options were defined, and why race/
ethnicity was important in the study. Authors should be prepared to provide study
protocol number(s) if requested.
Ethical Treatment of Animals. If animal experiments were performed, authors
must affirm that the research protocol was approved by the appropriate institutional
review boards or ethics committees for animal experiments and that regulations
concerning the use of animals in research were adhered to. Authors should be
prepared to provide study protocol number(s) if requested.
Copyright. Copyright of published manuscripts is held by the American Society for
Investigative Pathology, which must receive the assignment of copyright from the
authors of accepted manuscripts. For US government employees, the above as-
signment applies only to the extent allowable by law. See http://www.asip.org/pubs/
ajprights.pdf for details. Requests to republish copyrighted materials, including the
planned use, should be directed to the Editorial Office at 301-634-7959 or
ajp@asip.org.
Through The American Journal of Pathology’s affiliation with PubMed Central,
articles that arise from NIH-funded research and are properly attributed as such will
be deposited in PubMed Central’s repository by the Journal, in accordance with
NIH’s Public Access to Research Initiative, to be made available to the public twelve
months after final print publication. Authors therefore should not complete a sepa-
rate deposit of their material but will be contacted by PubMed Central for grant
verification once the manuscript has been received by the NLM submission system.
Contact the Editorial Office regarding permission to deposit manuscripts in other
government-sponsored repositories in cases where The American Journal of Pa-
thology does not have a system in place to automatically deposit materials on behalf
of their authors. Deposit of accepted or published manuscripts in any non-AJP
repository without prior permission by the Journal is a violation of copyright.
Embargo Policy. All information regarding the content of submitted or accepted
manuscripts is strictly confidential. Information contained in or about accepted
articles cannot appear in print, audio, video, or digital form or be released by the
news media until the Journal embargo date has passed, not to exceed the publi-
cation date of the article. For detailed information on embargo release dates or for
news media requests for preprint copies of specific articles, contact the Editorial
Office at 301-634-7959 or ajp@asip.org.
Scientific Misconduct. According to the US Office of Research Integrity (http://
ori.dhhs.gov/), “fabrication is making up data or results and recording or reporting
them; falsification is manipulating research materials, equipment, or processes, or
changing or omitting data or results such that the research is not accurately repre-
sented in the research record; plagiarism is the appropriation of another person’s
ideas, processes, results, or words without giving appropriate credit.” The Journal
has a zero tolerance policy for such matters. For details regarding how the Journal
handles such matters, see the later section on Allegations of Misconduct.
Fabrication of Data. Any evidence of fraudulent methods, data, or data analysis may
prompt the Editors to request an explanation and access to original data, which the
authors must supply.
Falsification of Data. The results presented in the manuscript must accurately
represent the data obtained in the course of authors’ studies; omission of contra-
dictory or negative data in an effort to support the main hypothesis is unacceptable.
Taking photographs under varied fields of view, light intensity, magnifications, or
contrast conditions without disclosing that the data are not unique to the present
study constitutes suspect scientific conduct. Further, unless serial sections are
used, the publication of identical-appearing images labeled with different staining
techniques in different papers raises legitimate questions. No specific feature within
an image may be enhanced, obscured, moved, removed, or introduced. The group-
ing of images from different parts of the same gel or blot, or from different gels or
blots, fields, or exposures must be made explicit by the arrangement of the figure
(eg, using dividing lines) and in the figure legend. Adjustments of brightness,
contrast, or color balance are acceptable only if they are applied to the whole image,
whether experimental or control image, and as long as they do not obscure or
eliminate any information present in the original (Portions adapted with permission
from the JCB). Any evidence of inappropriate manipulation may prompt the Editors
to request an explanation and access to original data, which the authors must make
available.
Plagiarism. Authors should carefully note that the use of another person’s data or
ideas without permission constitutes plagiarism. Authors may not republish copy-
righted Journal material in whole or in part without the express permission of the
copyright holder, the American Society for Investigative Pathology. Likewise, copy-
righted material previously published in another form may not be published in the
Journal without express permission from the original copyright holder. These rules
cover work previously written by the authors. Authors wishing to republish images,
tables, or text should provide proof of such permission with their submission and
should include the appropriate attribution in the figure or table legend or in the text.
Redundant Publication. “Redundant (or duplicate) publication is publication of a paper
that overlaps substantially with one already published in print or electronic media,” as
definedby theUniformRequirements forManuscriptsSubmitted toBiomedical Journals
(http://www.icmje.org). Authors must certify upon submission that the manuscript has
not been accepted or published elsewhere and that it is not currently under review at
another journal. Likewise,manuscripts under consideration by the Journal should not be
submitted or published elsewhere. Publication of short abstracts inmeeting proceedings
does not violate this standard. Submissions will be ineligible for review if previously
published in any form (print or online) other than as an abstract. This includes any public
posting of raw manuscripts or pre-reviewed material. If there is any doubt, the authors
should contact the Editorial Office for guidance.
Reviewer Conduct
Peer Review Process. Reviewers are expected to take their obligation seriously
and to consider carefully the merits of the manuscript being assessed. Any delays
in completing a review should be brought to the immediate attention of the Editorial
Office so that we may assess the situation and make adjustments as needed. It is
the practice of The American Journal of Pathology to conduct a blinded peer-review
process; it is considered a violation of this process for peer reviewers to identify
themselves or attempt to communicate directly with authors regarding the reviewed
manuscript without the express permission of the Editors. The Editors will consider
any deliberate ethical violation during peer review of a manuscript to be actionable
misconduct, the potential results of which may be reporting of conduct to the
Reviewer’s governing institution, dismissal as a peer reviewer for the Journal, and/or
the denial to consider any future submissions to the Journal.
Confidentiality. The manuscript is considered a privileged communication. When
reviewing a manuscript for the Journal, the peer reviewer takes responsibility for
maintaining its confidentiality. Reviewers should not retain copies of submitted
manuscripts for personal use after completing their review. Reviewers are not
allowed to make any use of the work described in the manuscript or take advantage
of the knowledge gained by reviewing it until and unless it is published.
If necessary, the manuscript may be discussed with a colleague in an effort to reach a
decision. In such instances, the Reviewermust inform the colleague of themanuscript’s
confidentiality and ask that they disclose any potential conflicts of interest. Information
regarding additional assistance (colleague’s name and disclosure information aswell as
a description of the level of assistance) should be included in the “Confidential Com-
ments to the Editor” portion of the online reviewer form.
Financial Disclosure and Conflicts of Interest. Reviewers must disclose to the
Editors any current or former affiliations (eg, employment, consultancies, board
membership, stock ownership, funding, honoraria, expert testimony, patents or
royalties, travel reimbursements, etc) with any organization or entity having a direct
financial or personal interest in the subject matter or materials discussed in the
manuscript that could bias their opinions of the manuscript. Reviewers should also
consider potential conflicts of interest arising from personal relationships or aca-
demic competition. Personal relationships include family members, colleagues
(such as collaborators, mentors, students, or trainees), or associates at a Review-
er’s institution. At least three years should elapse between the ending of such a
relationship and participation in any review. However, for certain relationships such
as student-mentor, three years may not be sufficient time, especially if both inves-
tigators continue to work in the same field. Thus, Reviewers must err on the side of
caution and decline any assignments in which the suggestion of a conflict or bias
could be raised. By agreeing to review a manuscript, Reviewers implicitly affirm that
any potential conflicts of interest have been disclosed to the Editors and that they
are able to provide an impartial review of the manuscript.
Editor Conduct
Peer Review Process. The Editor-in-Chief, Senior Associate Editor, Associate
Editors, and Special Associate Editor are expected to take their obligation seriously
and to maintain the highest standard of ethics during the peer-review process.
Editors should perform their editorial duties without bias for or against any person or
institution. Any delays in completing the disposition of a manuscript should be
brought to the immediate attention of the Editorial Office so that the situation may be
resolved. It is considered a violation for Editors to communicate directly with authors
regarding their manuscript outside of normal editorial practices. It is also a violation
for the Editors to reveal Reviewers’ names to authors without Reviewer consent; as
the Journal conducts a blinded peer-review process, such revelations are extremely
rare. Any deliberate ethical violation during peer review of a manuscript is consid-
ered to be actionable misconduct, the potential results of which may be reporting of
conduct to the Editor’s governing institution, dismissal as an Editor for the Journal,
and/or the denial to consider any future submissions to the Journal.
Editors should respect author requests to exclude specific reviewers due to prior
collaborations, known conflicts of interest, or direct competition when such requests
are well-founded; however, Editors have the authority to utilize such a reviewer if
they feel it is necessary for expert peer review. Such decisions should be made only
after careful consideration and after other options have been exhausted.
Confidentiality. The Editors are subject to the same confidentiality requirements as
Reviewers. Further, Editors must not disclose information about manuscripts (in-
cluding their receipt, content, status in the reviewing process, Reviewers’ com-
ments, or final disposition) to anyone other than the authors, Reviewers, and Journal
staff. Editors should not retain copies of submitted manuscripts for personal use
after completing their disposition. Editors are not allowed to make any use of the
work described in the manuscript or take advantage of the knowledge gained by
reviewing it until and unless it is published.
Financial Disclosure and Conflicts of Interest. Editors must also carefully con-
sider whether there exist any current or former affiliations (eg, employment, consul-
tancies, board membership, stock ownership, funding, honoraria, expert testimony,
patents or royalties, travel reimbursements, etc) with any organization or entity
having a direct financial or personal interest in the subject matter or materials
discussed in the manuscript that could bias their opinions of the manuscript. Editors
should also consider potential conflicts of interest arising from personal relationships
or academic competition. Personal relationships include family members, col-
leagues (such as collaborators, mentors, students, or trainees), or associates at the
Editor’s institution. At least three years should elapse between the ending of such a
relationship and participation in any review. However, for certain relationships such
as student-mentor, three years may not be sufficient time, especially if both inves-
tigators continue to work in the same field. Thus, Editors must err on the side of
caution and decline any assignments in which the suggestion of a conflict or bias
could be raised. By agreeing to review a manuscript, the Editor implicitly affirms that
conflicts do not exist. In cases where the Editor-in-Chief has a conflict of interest, the
Senior Associate Editor or another Associate Editor will handle the full disposition of
the manuscript.
Staff Conduct
Peer Review Process. When handling a manuscript for the Journal, the Journal
staff is expected to interact courteously and respectfully with authors, Reviewers,
and Editors. They should not misrepresent the review process to authors or Re-
viewers. They should not forge, fabricate, or alter the scientific content of Reviewer
comments. They should ensure timely disposition of reviewed manuscripts and
publication of accepted manuscripts.
Confidentiality. The Journal staff is subject to the same confidentiality standards as
Editors. It is considered a violation of this confidentiality for staff to reveal Reviewer
names or to communicate directly with authors regarding their manuscript outside of
normal editorial practices.
Allegations of Misconduct
Reporting SuspectedMisconduct. Tomaintain the integrity and high standards of
the scientific publishing process, the Journal welcomes reporting of possible mis-
conduct or other concerns related to manuscripts published or under review by the
Journal. Suspected misconduct relating to authors, Reviewers, or Editors should be
reported in writing to the Editorial Office at The American Journal of Pathology, 9650
Rockville Pike, Bethesda, Maryland, USA 20814-3993 or ajp@asip.org. Issues
relating to staff conduct should be directed to the ASIP Executive Officer at Amer-
ican Society for Investigative Pathology, 9650 Rockville Pike, Bethesda, Maryland,
USA 20814-3993 or mesobel@asip.org. Willful misconduct does not include inci-
dents of honest misjudgment or inadvertent error.
The anonymity of the whistleblower(s) will be maintained throughout these proce-
dures. With respect to all other communications arising from examination of mis-
conduct, the ability to effectively investigate and administer an allegation of scientific
misconduct shall be carefully balanced with the need to maintain confidentiality in
order to protect the rights and reputations of all concerned.
Procedures for Suspected Author Misconduct. Upon written notification of pos-
sible author misconduct, the Editors and Editorial Office will first perform a prelimi-
nary evaluation to determine if there is merit to the claims. The Editors reserve the
right to involve the Publications Committee, Executive Officer of ASIP, and/or legal
counsel as deemed appropriate. If the manuscript is currently under review, the
review process will be put on hold pending resolution. If the claims appear to have
merit, the next step is to contact the authors.
The Editor-in-Chief will contact all authors, and the corresponding author will be
asked to respond formally to the Editors’ concerns, and may be asked to provide
source data, within 30 days. Authors are expected to cooperate fully and in good
faith. Upon review of said data and explanation, the Editors and Editorial Office will
determine whether an innocent error was committed (requiring publication of a
Correction or Retraction) or whether further reporting or investigation is warranted.
If needed, the authors’ institutions and/or funding agencies will be contacted, as it is
not the responsibility of the Journal to perform such an investigation. During the
investigation, the Journal will not receive or review new manuscripts from authors
named in the disputed manuscript.
The appropriate authorities at the authors’ institutions and/or funding agencies will
be notified of the original complaint and may be asked to conduct an independent
investigation. Once an investigation has begun, the Editors may choose to publish
a Note of Concern informing the scientific community that an investigation is under-
way regarding the manuscript in question. The investigation is expected to proceed
in a timely manner, and upon completion of an investigation, the institution should
quickly notify the Journal of its findings.
If an institution or funding agency declines to conduct an investigation on a timely
basis, or if an author does not have such an affiliation, the Journal may conduct its
own investigation.
If all authors are cleared of any wrongdoing, an unpublished manuscript may
re-enter the review process. If a Note of Concern was published, the Journal will
publish a Correction to rectify the matter in the public record.
Upon receiving final determination of misconduct (including final appeal), the Jour-
nal may publish a Correction, Note of Concern, or Retraction, depending on the
findings of the investigation and the effect on the paper as a whole. If misconduct is
determined by the authors’ institutions, then the Editorsmay request that the authors
retract their paper. If the authors refuse, the Journal will notify all authors of the intent
to publish a Retraction, to which the authors have 30 days to respond. The final
Retraction will describe the reason for retraction as well as a list of authors agreeing
(and if necessary those disagreeing) with the retraction. For unpublished manu-
scripts, the manuscript may be rejected or acceptance may be rescinded.
At any point during the course of the investigation, the authors may withdrawal their
unpublished manuscript or request a Retraction. If this occurs prior to formal inves-
tigation, the Editors may still determine to inform the authors’ institutions and/or
funding agencies.
These procedures do not supersede or diminish the general authority of the Journal
to reject a manuscript as part of the review process.
Procedures for Suspected Editorial Misconduct (Reviewers, Editors, Staff).
Upon written notification of possible editorial misconduct, the Editors and/or Editorial
Office will first perform a preliminary evaluation to determine if there is merit to the
claims. If the complaint involves an Editor or Journal staff, that person will be
excluded from any review. The Editors reserve the right to involve the Publications
Committee, Executive Officer of ASIP, and/or legal counsel as deemed appropriate.
If the claims appear to have merit, the next step is to contact the person involved.
The Editor-in-Chief or Executive Officer of the Society will contact the person involved,
requesting a formal response to the concerns within 30 days. Upon review of said
explanation, the Editors and Editorial Office will determine whether an innocent error
was committed or whether further investigation or reporting is warranted. If needed, the
person’s institution and/or funding agency will be contacted, as it is not the responsibility
of the Journal to perform such an investigation. During the investigation, the Editor or
Reviewer will be excluded from reviewing or submitting new manuscripts.
The appropriate authorities at the person’s institution will be notified of the original
complaint and may be asked to conduct an independent investigation. The inves-
tigation is expected to proceed in a timely manner, and upon completion of an
investigation, the institution should quickly notify the Journal of its findings.
Upon receiving final determination of misconduct (including final appeal), the Jour-
nal may publish a Note of Concern if the disposition of a manuscript(s) was affected.
Depending on the severity of the misconduct committed, the Editor, Reviewer, or
Journal staff may be relieved of all future Journal-related duties.
These procedures do not supersede or diminish the general authority of the Journal
to dismiss an Editor, Reviewer, or Journal staff.
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